Aummune develops a first-of-its-kind individual drug-customization platform that utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional aptamer drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses
Member count: 11-50
Investors 1
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |